EVQLV

EVQLV Welcomes Chief Scientific Officer Richard Fox

EVQLV Welcomes Chief Scientific Officer Richard Fox

NEW YORK, November 9, 2020 -- EVQLV’s founders are thrilled to (officially) announce that Richard Fox has joined our team as Chief Scientific Officer. Dr. Fox spent nearly two decades at the Fred Hutchinson Cancer Research Center. Within industry he led virology...

read more
EVQLV Joins Endless Frontier Labs Incubator

EVQLV Joins Endless Frontier Labs Incubator

NEW YORK, September 21, 2020 -- EVQLV has been invited to join the Life Science Track of the prestigious Endless Frontier Labs (EFL) incubator. The nine-month program runs each year from October through May. The program provides: Guidance from industry executives to...

read more
EVQLV CEO’s Article Published in ‘Life Science Leader’

EVQLV CEO’s Article Published in ‘Life Science Leader’

Examining AI as automated, assistive, analytical, accelerated, or augmented intelligence is a framework for thinking about how to apply these tools to data in ways that are aligned with an organization’s goals. This framework is designed to allow those who do not routinely build or employ AI to avoid the overhyped rhetoric of AI and consider the practical outcomes of employing it.

read more
EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV’s Collaboration with Twist Bioscience aims to Discover and Validate Novel Antibody Therapies

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a collaboration with Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, to discover novel antibody-based therapies.

read more

Pin It on Pinterest